I spoke to Novo about that. It will depend on a few factors.Hey guys just a quick question, Do you think they will get rid of Novarapid and swap everyone over to Fiasp in due course.
The reasons I am asking this is.
1. Made by the same company
2. Works Faster
3. Same price as Novarapid.
I've not seen that anywhere. Do you have any sources for that?I understood there were limitation to Fiasp in terms of high volume injections (more than 10u).
Usually when a drug company comes out with a "better" version of their patented drug (Novorapid, made by Novo Nordisc) it means that patent is due to run out. That's what happened to Lantus, made by Sanofi, so they came out with Toujeo right before Lantus went generic (Basaglar). The other thing they do is combine the drug due to expire with a new drug and they patent the combination. Or they change the delivery system and patent that. Drug companies are pretty crafty about making sure they can charge us up the **** for their stuff. Right?
Supposedly so is Toujeo, longer acting/peakless, just like Fiasp is supposedly shorter/faster acting. Whether that leads to lower A1C's is the question. Does it? Did they compare it to Novorapid in a randomized study? I'd be interested in seeing that if it was done. At least in the US when a popular drug does generic the price doesn't come down much the first year because our FDA only lets one company come out with a competitor drug. So for me Basaglar doesn't cost any less than Lantus did (and Lantus came in 10cc vials, Basaglar only comes in 3cc disposable pens). But I figure eventually the price will come down. Where I work at a Veterans Administration healthcare facility we prescribe a LOT of Lantus to Type 2 diabetics, so the savings could be huge for the government eventually. When Lipitor went generic the price we pay per pill went from about $1 to about 5 cents.While what you're saying to probably right, in this case Fiasp is actually a better version
I'll let you know if my hba1c is better on Toujeo300, compared to humulin m3. I read on-line it had good results, if anything a tiny bit better than lantus.Supposedly so is Toujeo, longer acting/peakless, just like Fiasp is supposedly shorter/faster acting. Whether that leads to lower A1C's is the question. Does it? Did they compare it to Novorapid in a randomized study? I'd be interested in seeing that if it was done. At least in the US when a popular drug does generic the price doesn't come down much the first year because our FDA only lets one company come out with a competitor drug. So for me Basaglar doesn't cost any less than Lantus did (and Lantus came in 10cc vials, Basaglar only comes in 3cc disposable pens). But I figure eventually the price will come down. Where I work at a Veterans Administration healthcare facility we prescribe a LOT of Lantus to Type 2 diabetics, so the savings could be huge for the government eventually. When Lipitor went generic the price we pay per pill went from about $1 to about 5 cents.
You won't have to wait too long. ONSET 3 and 4 are comparing Fiasp and Novorapid in a double blind randomised study. The results are due out later this year. I know a few of the involved HCPs (and one of the clinics involved is mine). According to the senior consultant, a number of people have identified they are on Fiasp, but the key point about the study is that it has taken normal T1s with Hba1C between 7.5% and 10% and used them. Most aren't as heavily engaged as most of us are. It will be very interesting to see the outcome.Supposedly so is Toujeo, longer acting/peakless, just like Fiasp is supposedly shorter/faster acting. Whether that leads to lower A1C's is the question. Does it? Did they compare it to Novorapid in a randomized study? I'd be interested in seeing that if it was done.